How i treat... by optimizing the blockade of the renin-angiotensin- aldosterone system;Comment je traite... en optimisant le blocage du système rénine-angiotensine-aldostérone

Revue Medicale de Liege

Volumn 63, Issue 4, 2008, Pages 174-181

  Schleich, F ^a   Krzesinski, J M ^a   Pierard L ^a   Scheen, A J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

ACE inhibitor; Aliskiren; AT1 receptor blocker; Heart failure; Hypertension; Nephropathy; Post infarct; Renin angiotensin system; Renin inhibitor

Indexed keywords

ALISKIREN; AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TAZKO; TELMISARTAN; TRANDOLAPRIL; VACCINE; VALSARTAN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INHIBITION KINETICS; KIDNEY DISEASE; MICROALBUMINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VACCINATION;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FUMARATES; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 44449088339     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Carey RM, Siragy HM. - Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev, 2003, 24, 261-271.
2. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. - Renin-angiotensin system and cardiovascular risk. Lancet, 2007, 369, 1208-1219.
3. Stojiljkovic L, Behnia R. - Role of renin angiotensin system inhibitors in cardiovascular and renal protection : a lesson from clinical trials. Curr Pharm Des, 2007, 13, 1335-1345.
4. Paul M, Poyan Mehr A, Kreutz R. - Physiology of local renin-angiotensin systems. Physiol Rev, 2006, 86, 747-803.
5. Kobori H, Nangaku M, Navar LG, Nishiyama A. - The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev, 2007, 59, 251-287.
6. Agadoa L Appel L, Bakris G, et al. - Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis : a randomized controlled trial. JAMA, 2001, 285, 2719-2728.
7. White WB. - Angiotensin-Converting enzyme inhibitors in the treatment of hypertension: an update. J Clin Hypertens, 2007, 9, 876-882.
8. Krzesinski JM, Xhignesse P. - Nouvelles directives en 2007 pour la prise en charge de l'hypertension artérielle. Rev Med Liège, 2007, 62, 566-574.
9. Cohn JN. - Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther, 2007, 24, 1290-1304.
10. Jorde UP. - Suppression of the renin-angiotensin-aldosterone system in chronic heart failure : choice of agents and clinical impact. Cardiol Rev, 2006, 14, 81-87.
11. Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. - Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag, 2007, 3, 937-945.
12. Weekers L, Scheen AJ, Rorive G. - Prévention de la néphropathie diabétique : de la microalbuminurie à l'insuffisance rénale terminale. Rev Med Liège, 2003, 58, 297-306.
13. Gurley SB, Coffman TM. - The renin-angiotensin system and diabetic nephropathy. Semin Nephrol, 2007, 27, 144-152.
14. Thomas GN, Tomlinson B. - Prevention of macrovascular disease in type 2 diabetic patients: blockade of the renin-angiotensin-aldosterone system. Curr Diabetes Rev, 2008, 4, 63-78.
15. Scheen AJ, Krzesinski JM. - ADVANCE : amélioration de la survie et réduction des complications vasculaires et rénales avec la combinaison fixe perindopril-indapamide chez le patient diabétique de type 2. Rev Med Liège, 2007, 62, 639-643.
16. Weir MR. - Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther, 2007, 29, 1803-1824.
17. Blumenfeld JD, Sealey JE, Mann SJ, et al. - Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin- aldosterone system in normotensive and hypertensive subjects. Am J Hypertens, 1999, 12, 451-459.
18. Struthers AD. - Aldosterone blockade in cardiovascular disease. Heart, 2004, 90, 1229-1234.
19. Dendorfer A, Dominiak P, Schunkert H. - ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol, 2005, 170, 407-442.
20. Burnier M, Brunner HR. - Angiotensin II receptor antagonists. Lancet, 2000, 355, 637-645.
21. Ram CV. - Direct renin inhibitors: a new approach to antihypertensive drug treatment. J Clin Hypertens, 2007, 9, 615-621.
22. Krzesinski JM, Montrieux Ch, Scheen AJ. - Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique : que nous dit l'Evidence Based Medicine ? Rev Med Liège, 2006, 61, 414-422.
23. White WB. - Angiotensin-Converting enzyme inhibitors in the treatment of hypertension : an update. J Clin Hypertens, 2007, 9, 876-882.
24. Thomas S, Geltman E. - What is the optimal angiotensin-converting enzyme inhibitor dose in heart failure? Congest Heart Fail, 2006, 12, 213-218.
25. Azizi M, Ménard J. - Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation, 2004, 109, 2492-2499.
26. Weber MA. - New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol, 2007, 100, 45J-52J.
27. Cohn JN, Goldman JM. - Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens, 2008, 21, 248-256.
28. Gradman AH, Kad R. - Renin inhibition in hypertension. J Am Coll Cardiol, 2008, 51, 519-528.
29. Lopez-Sendon J, Swedberg K, McMurray J, et al, for the Task Force on ACE-inhibitors of the European Society of Cardiology. - Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J, 2004, 25, 1454-1470.
30. Krzesinski J-M. - Preterax® La première association fixe faiblement dosée contenant un inhibiteur d'enzyme de conversion et un diurétique thiazide. Rev Med Liège, 2004, 59, 601-606.
31. Scheen AJ. - L'étude HOPE, un essai clinique bicéphale aux résultats contrastés. Rev Med Liège, 2000, 55, 64-66.
32. Scheen AJ, Legrand V. - L'étude EUROPA : protection cardio-vasculaire avec le perindopril chez les patients avec coronaropathie stable. Rev Med Liège, 2003, 58, 713-716.
33. Krzesinski JM, Scheen AJ. - Exforge® : première association d'un antagoniste calcique (bésylate d'amlodipine) et d'un inhibiteur des récepteurs de l'angiotensine II (valsartan). Rev Med Liège, 2007, 62, 688-694.
34. Ramasubbu K, Mann DL, Deswal A. - Anti-angiotensin therapy : new perspectives. Cardiol Clin, 2007, 25, 573-580.
35. Kulbertus H. - L'étude CHARM. Rev Med Liège, 2003, 58, 646-652.
36. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. - A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345, 1667-1675.
37. Atlas SA. - The renin-angiotensin aldosterone system : pathophysiological role and pharmacologic inhibition. J Manag Care Pharm, 2007, 13, S9-S20.
38. Staessen JA, Li Y, Richart T. - Oral renin inhibitors. Lancet, 2006, 368, 1449-1456.
39. Philips JC, Weekers L, Scheen AJ. - L'étude CALM ou intérêt de combiner un inhibiteur de l'enzyme de conversion et un antagoniste du récepteur de type 1 de l'angiotensine II dans le traitement de la néphropathie diabétique. Rev Med Liège, 2001, 56, 126-128.
40. Bakris GL, Ruilope L, Locatelli F, et al. - Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk : results of the IMPROVE trial. Kidney Int, 2007, 72, 879-885.
41. Nakao N, Yoshimura A, Morita H, et al. - Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet, 2003, 361, 117-124.
42. McMurray JJ, Ostergren J, Swedberg K, et al. - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet, 2003, 362, 767-771.
43. Pitt B, Zannad F, Remme WJ, et al for the Randomized Aldactone Evaluation Study Investigators. - The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med, 1999, 341, 709-717.
44. Krzesinski JM. - L'hyperkaliémie, ce nouveau tueur ? Rev Med Liège, 2005, 60, 222-226.
45. Weir RA, McMurray JJ, Puu M, et al. - Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail, 2008, 10, 157-163.
46. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. - Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med, 2003, 349, 1893-1906.
47. The ONTARGET Investigators. - Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med, 2008, 358, 1547-1559.
48. Scheen AJ, Krzesinski JM. - ONTARGET : Protection comparable du telmisartan et du ramipril et absence de bénéfice de la combinaison chez des patients à haut risque vasculaire. Rev Med Liège, 2008, 63, 4, 214-220.
49. Danilczyk U, Penninger JM. - Angiotensin-converting enzyme II in the heart and the kidney. Circ Res, 2006, 98, 463-471.
50. Burns KD. - The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens, 2007, 16, 116-121.
51. Trask AJ, Ferrario CM. - Angiotensin-(1-7) : pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev, 2007, 25, 162-174.
52. Aulakh GK, Sodhi RK, Singh M. - An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci, 2007, 81, 615-639.
53. Tissot AC, Maurer P, Nussberger J, et al. - Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure : a double-blind, randomised, placebo-controlled phase IIa study. Lancet, 2008, 371, 821-827.